ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0080

One Point Increase in the Initial Damage as Measured by the Damage Index for Antiphospholipid Syndrome Predicts Mortality in a Multi-Ethnic Group of Thrombotic Antiphospholipid Syndrome Patients

Pedro Gaspar1, Filipa Farinha2, Zara Sayar3, Maria Efthymiou,4, Hannah Cohen3 and David Isenberg2, 1Department of Internal Medicine 2, University Hospital of Santa Maria, Lisbon, Portugal, 2Centre for Rheumatology, University College London, London, United Kingdom, 3Department of Haematology, University College London Hospitals NHS Foundation Trust, London, United Kingdom, 4Haemostasis Research Unit, Department of Haematology, University College London, London, United Kingdom

Meeting: ACR Convergence 2021

Keywords: antiphospholipid syndrome, Damage Index, Mortality

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 6, 2021

Title: Antiphospholipid Syndrome Poster (0069–0083)

Session Type: Poster Session A

Session Time: 8:30AM-10:30AM

Background/Purpose: The chronic and recurrent nature of antiphospholipid syndrome (APS) leads to damage accrual that impairs long-term functional status and survival. The Damage Index for Antiphospholipid Syndrome (DIAPS) is a validated instrument designed to capture the damage accrual in thrombotic APS, but it is not known whether it correlates with mortality. We aim to determine whether early damage, as measured by the DIAPS, predicts long-term mortality in thrombotic APS.

Methods: We carried out a retrospective analysis of all medical records to calculate the yearly DIAPS score of 197 thrombotic APS patients attending the Rheumatology and/or Haematology clinics at a tertiary hospital for up to 43 (median 10) years. Patients fulfilled the 2006 Sydney classification criteria. The disease onset was the time the first thrombotic event related to APS was diagnosed. Early damage refers to damage present at six months after the disease onset. Early DIAPS increase refers to the increase of at least one point from the initial DIAPS score within the first five years after the disease onset. DIAPS score is shown as median (interquartile range, IQR). We used logistic, and uni and multivariable Cox regression models to analyse risk factors affecting mortality. Survival was analysed through the Kaplan-Meier method.

Results: The median age at APS onset was 40 (IQR 51-28) years, with a female (71%) and primary APS (66%) preponderance. Caucasian ethnicity was the most prevalent (72%), followed by Asian (10%), Afro-Caribbean (9%) and other (9%). Damage developed in 143 (73%) patients with a median DIAPS score of 1 (IQR 2-0) at the last visit. Early damage was present in 69 (35%) patients. Early DIAPS scored low values in the whole group (0, IQR 1-0). We identified 23 fatalities (12%). Patients who died had higher last DIAPS (2, IQR 3-1 vs. 1, IQR 2-0, p=0.012) but similar early DIAPS score (0, IQR 1-0 vs. 0, IQR 1-0, p=0.318) compared to those who survived. Secondary APS (HR 3.07, 95% CI 1.32-7.12, p=0.009), male gender (HR 3.14, 95% CI 1.35-7.33, p=0.008) and age at APS onset ≥40 years (HR 5.34, 95% CI 1.96-14.53, p=0.001) were risk factors for death. Early damage was not associated with death (HR 1.65, 95% CI 0.73-3.78, p=0.231). Conversely, early DIAPS increase, present in 29% (53/181) of patients, was associated with death (HR 5.40, 95% CI 2.33-12.52, p< 0.001), even after adjusting individually for APS category (secondary, HR 5.05, 95% CI 2.18-11.72, p< 0.001), gender (male, HR 5.40, 95% CI 2.29-12.73, p< 0.001) and age at APS onset (≥40 years, HR 3.41, 95% CI 1.43-8.20, p=0.006). Figure 1 shows the survival analysis. Having a first arterial thrombotic event was associated with early damage (OR 7.24, 95% CI 3.74-14.03, p< 0.001), but not with early DIAPS increase (OR 1.22, 95% CI 0.64-2.33, p=0.539) nor with the risk of death (HR 1.85, 95% CI 0.79-4.27, p=0.151).

Conclusion: These findings suggest that damage accrual accessed by DIAPS is associated with increased mortality in a large multi-ethnic group of APS patients. In particular, an increase of at least one point on DIAPS in the first five years after disease onset, but not early damage, is an important predictor of mortality regardless of the nature of the first thrombotic event, gender, APS category and age.

Fig. 1 – Kaplan–Meier curve showing cumulative survival according to the presence of early DIAPS increase.


Disclosures: P. Gaspar, None; F. Farinha, None; Z. Sayar, None; M. Efthymiou,, None; H. Cohen, Bayer Healthcare, 5, 6, 12, Support to attend scientific meetings; Honoraria for lectures at symposia paid to University College London Hospitals Charity, UCB Biopharma, 2, 12, Consultancy fees paid to University College London Hospitals Charity; D. Isenberg, None.

To cite this abstract in AMA style:

Gaspar P, Farinha F, Sayar Z, Efthymiou, M, Cohen H, Isenberg D. One Point Increase in the Initial Damage as Measured by the Damage Index for Antiphospholipid Syndrome Predicts Mortality in a Multi-Ethnic Group of Thrombotic Antiphospholipid Syndrome Patients [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/one-point-increase-in-the-initial-damage-as-measured-by-the-damage-index-for-antiphospholipid-syndrome-predicts-mortality-in-a-multi-ethnic-group-of-thrombotic-antiphospholipid-syndrome-patients/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/one-point-increase-in-the-initial-damage-as-measured-by-the-damage-index-for-antiphospholipid-syndrome-predicts-mortality-in-a-multi-ethnic-group-of-thrombotic-antiphospholipid-syndrome-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology